Kalia Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kalia Health is a San Diego-based, early-stage biotech company founded in 2020, targeting the urgent need for better preeclampsia diagnostics. The company is developing a point-of-care, urine-based test for at-home use to enable early detection and prompt medical intervention. It has gained significant non-dilutive funding and validation through awards, most notably a Grand Challenges Grant from the Bill & Melinda Gates Foundation. Kalia Health operates as a private, pre-revenue diagnostics company with a clear focus on addressing health disparities in maternal care.

Maternal HealthObstetrics

Technology Platform

Urine-based point-of-care diagnostic platform for at-home detection of proteinuria and other biomarkers associated with preeclampsia.

Opportunities

The massive global burden of preeclampsia, especially in low-resource settings, presents a clear unmet need for decentralized diagnostics.

Designing for equity first could enable adoption in both global health markets and underserved populations in developed nations, facilitated by partnerships with NGOs and public health systems.

Non-dilutive grant funding from prestigious sources validates the mission and provides runway.

Risk Factors

The company faces significant technical risk in developing a sufficiently accurate and user-friendly at-home test, and regulatory risk in obtaining FDA or other clearance for a new diagnostic.

Commercialization risk is high, as market adoption will require convincing healthcare systems and building distribution in challenging low-resource environments.

Competitive Landscape

Competition includes traditional lab-based urine tests and clinic-based point-of-care dipsticks. Other companies are exploring novel biomarkers (e.g., sFlt-1/PlGF ratio) for preeclampsia, but these are typically lab-based. Kalia's primary differentiation is its focus on an affordable, truly at-home, self-administered format designed specifically for low-resource settings.

More companies in Diagnostics & Precision Medicine →More companies in United States →